Naproxen - Iroko Pharmaceuticals

Drug Profile

Naproxen - Iroko Pharmaceuticals

Alternative Names: IP 890; Nano-formulated naproxen - Iroko Pharmaceuticals; SoluMatrix® Naproxen

Latest Information Update: 23 Feb 2016

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator iCeutica
  • Developer Iroko Pharmaceuticals
  • Class Antipyretics; Antirheumatics; Naphthaleneacetic acids; Nonsteroidal anti-inflammatories; Small molecules
  • Mechanism of Action Cyclooxygenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Musculoskeletal pain
  • No development reported Dental pain

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 01 Mar 2013 Short review: double checked that the results for dental pain were actually presented at a rheumatology conference. Same results are on CT.gov so all correct.
  • 01 Mar 2013 Iroko Pharmaceuticals plans phase III trials for Musculoskeletal pain (associated with osteoarthritis)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top